Secondary central precocious puberty in female

Summary

Secondary central precocious puberty in female (MONDO:0958355) is a disease. A subtype of central precocious puberty — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secondary central precocious puberty in female
Mondo ID	MONDO:0958355
Orphanet	650082
UMLS	C5816762
MedGen	1853148
GARD	0027029
Is cancer (heuristic)	no

Disease family

This is a subtype of central precocious puberty. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › reproductive system disorder › gonadal disorder › precocious puberty › central precocious puberty › secondary central precocious puberty in female

Related subtypes (6): central precocious puberty 1, precocious puberty, central, 2, idiopathic central precocious puberty, secondary central precocious puberty, central precocious puberty in male, genetic central precocious puberty in female

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.